Middle East and Asia Pacific Cell and Gene Therapy Market, by Therapy Type (Cell Therapy (Stem Cells, T Cells, Dendritic Cells, and NK Cells) and Gene Therapy (Germline Gene Therapy and Somatic Gene Therapy)), by Indication (Dermatology, Musculoskeletal,

Middle East and Asia Pacific Cell and Gene Therapy Market, by Therapy Type (Cell Therapy (Stem Cells, T Cells, Dendritic Cells, and NK Cells) and Gene Therapy (Germline Gene Therapy and Somatic Gene Therapy)), by Indication (Dermatology, Musculoskeletal, Oncology, Immunology, Cardiology & Neurology, and Others), by Technology (Lentiviral Vector, Plasmid DNA, and AAV), and by Region (Middle East and Asia Pacific) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Cell therapy is the administration of living cells in patients for the treatment of a disease such as oncology, Immunology and others. The source of a cell can be autologous or allogeneic, which can be derived from stem cells such as bone marrow. Stem cells therapy is used in bone marrow transplantation. Gene therapy is the introduction, removal, or change in the patient's genetic code for the treatment of a disease. Moreover, it modifies the expression of an individual’s genes or repairs abnormal genes. The therapy involves the administration of nucleic acid (DNA/RNA) with carriers called vectors.

Market Dynamics

Key players are focusing on product approvals and launches to strengthen their position in the Middle East and Asia Pacific cell and gene therapy market. For instance, in March 2021, Novartis received Singapore Health Sciences Authority (HSA) approval for Kymriah (tisagenlecleucel), as the first commercial chimeric antigen receptor T-cell (CAR-T) therapy in Singapore under the new cell, tissue, and gene therapy products (CTGTP) regulatory framework.

Furthermore, in February 2021, the commercial manufacturing of Novartis’s Kymriah was approved by Therapeutic Goods Administration (TGA) in Australia.

Key features of the study:

• This report provides an in-depth analysis of the Middle East and Asia Pacific cell and gene therapy market, provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Middle East and Asia Pacific cell and gene therapy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Novartis International AG, Pfizer, Inc., Sanofi S.A., Amgen, Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Bluebird Bio, Inc. (Celgene Corporation), Gene biotherapeutics, Sibiono GeneTech Co. Ltd., Kolon TissueGene, Inc., Horama S.A., MeiraGTx Limited, Gilead Sciences, Inc., Biogen INC., Organogenesis, Inc., JCR Pharmaceuticals Co. Ltd, uniQure N.V., WuxiAppTec, Lonza, and Immuneel Therapeutics Pvt Ltd
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The Middle East and Asia Pacific cell and gene therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Middle East and Asia Pacific cell and gene therapy market

Detailed Segmentation:

• Middle East and Asia Pacific Cell and Gene Therapy Market, By Therapy Type:
• Cell Therapy
• Stem Cells
• T Cells
• Dendritic Cells
• NK Cells
• Gene Therapy
• Germline Gene Therapy
• Somatic Gene Therapy
• Middle East and Asia Pacific Cell and Gene Therapy Market, By Indication:
• Dermatology
• Musculoskeletal
• Oncology
• Immunology
• Cardiology & Neurology
• Others
• Middle East and Asia Pacific Cell and Gene Therapy Market, By Technology:
• Lentiviral Vector
• Plasmid DNA
• AAV
• Middle East and Asia Pacific Cell and Gene Therapy Market, By Region:
• Middle East
• By Therapy Type
• Cell Therapy
• Stem Cells
• T Cells
• Dendritic Cells
• NK Cells
• Gene Therapy
• Germline Gene Therapy
• Somatic Gene Therapy
• By Indication
• Dermatology
• Musculoskeletal
• Oncology
• Immunology
• Cardiology & Neurology
• Others
• By Technology
• Lentiviral Vector
• Plasmid DNA
• AAV
• By Country
• Kingdom of Saudi Arabia
• UAE
• Israel
• Iran
• Jordan
• Rest of Middle East
• Asia Pacific
• By Therapy Type
• Cell Therapy
• Stem Cells
• T Cells
• Dendritic Cells
• NK Cells
• Gene Therapy
• Germline Gene Therapy
• Somatic Gene Therapy
• By Indication
• Dermatology
• Musculoskeletal
• Oncology
• Immunology
• Cardiology & Neurology
• Others
• By Technology
• Lentiviral Vector
• Plasmid DNA
• AAV
• By Country
• South East Asia
• Philippines
• Malaysia
• Singapore
• Thailand
• Vietnam
• Rest of South East Asia
• Taiwan
• Hong Kong
• Macau
• Japan
• South Korea
• India
• Australia
• China
• Rest Of Asia pacific
• Company Profiles
• Novartis International AG*
• Company Overview
• Product Portfolio
• Financial Overview
• Key Highlights
• Market Strategies
• Pfizer, Inc.
• Sanofi S.A.
• Amgen, Inc.
• Regeneron Pharmaceuticals, Inc.
• F. Hoffmann-La Roche AG
• Bluebird Bio, Inc. (Celgene Corporation)
• Gene biotherapeutics
• Sibiono GeneTech Co. Ltd.
• Kolon TissueGene, Inc.
• Horama S.A.
• MeiraGTx Limited
• Gilead Sciences, Inc.
• Biogen INC.
• Organogenesis, Inc.
• JCR Pharmaceuticals Co. Ltd
• uniQure N.V.
• WuxiAppTec
• Lonza
• Immuneel Therapeutics Pvt Ltd

“*” marked represents similar segmentation in other categories in the respective section.